AseBio and Alira Health Partner to Foster Market Access for Biotech Startups

News
Published on:
September 27, 2022

Alira Health, a global healthcare advisory and technology company, and AseBio, the Spanish Bioindustry Association, are joining forces to support Spanish biotech companies looking to enter new markets.

Together, AseBio and Alira Health will provide a market access mentoring program for AseBio members to promote access to innovation.

Alira Health, a member of AseBio since Spring 2022, will pair its experienced market access consultants with companies to improve their value proposition, navigate the ecosystem, and properly define their market access needs. The program features a 40-hour service package that includes an initial meeting, background analysis, tailored orientation session for market access and pricing, and gap analysis.

It is a pleasure for us as Alira Health to collaborate with AseBio in this mentoring program. We hope that this will allow us to help biotech companies have better access to the market, and in addition, train companies in areas where they need development.”
Chus Castillo Vice President, Market Access, Alira Health (Iberia)

The program will start in November 2023, and application is open to all AseBio SMEs. Three companies will be selected for the inaugural program.

Ion Arocena, General Director at AseBio, and Chus Castillo, Vice President of Market Access at Alira Health (Iberia), attended the signing event.

“It is a pleasure for us as Alira Health to collaborate with AseBio in this mentoring program. We hope that this will allow us to help biotech companies have better access to the market, and in addition, train companies in areas where they need development”, says Chus Castillo, Vice President of Market Access at Alira Health (Iberia).

Would you like to learn more about Alira Health’s partnership with AseBio? Watch this interview with our team.

Related news

Blog March 20, 2023
The State of Market Access in Italy 2023
To learn about the state of market access in Italy today, we spoke with Giovanni Firenze, Director of Market Access Italy for Alira Health, who attended the recent 2023 Conferenza Nazionale(...)
Drug Development Market Access Pharma
Events March 6, 2023
World EPA Congress 2023
We are pleased to share that we will be participating in World EPA Congress 2023 as speakers and sponsors. World Evidence, Pricing and Access Congress is Europe’s largest congress(...)
Biotech Market Access Pharma Real-World Evidence
Blog March 6, 2023
Market Access in Catalonia: 2022 Trends and What’s Next
Alira Health contributed to the recently published 2022 BioRegion Report, the most extensive analysis of the assets, achievements, and trends in the life sciences and healthcare sector(...)
Biotech Market Access MedTech
Events March 1, 2023
Emerging Medtech Summit 2023
We are excited to announce that we will attend and speak at Emerging Medtech Summit 2023, the must-attend medtech partnering and investment event for leading medtech startup CEOs, investors(...)
MedTech Startups
Events February 28, 2023
2023 MedTech Color Pitch Competition
We are proud to share that we are partnering with 2023 MedTech Color Pitch Competition. The MedTech Color Pitch Competition searches for the next generation of fearless founders innovating(...)
MedTech Startups
News February 27, 2023
Alira Health Partners with MedTech Innovator to Help Accelerate Startup Growth
Alira Health is pleased to partner with MedTech Innovator on their joint mission to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system.
Innovation MedTech Startups
News February 23, 2023
Silicon Valley Bank Leads Group of Sponsors Funding LabCentral Ignite Programs to Support Underrepresented Life Sciences Entrepreneurs
Silicon Valley Bank has assembled a diverse group of organizations, including Wilson Sonsini Goodrich & Rosati, EisnerAmper, and Alira Health, to sponsor LabCentral Ignite, a first-and-only-of-its-kind(...)
Biotech Diversity Life Sciences
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.